In 2024, users of the well-known corticosteroid inhalers Flovent HFA or Flovent Diskus will have to move to a new medicine to manage their asthma as GlaxoSmithKline (GSK), the company that makes them has decided to stop its production.
According to GSK, they would instead create an approved generic version using the same device design and composition.
However, physicians are worried about the difficulties patients may encounter in obtaining medication in the event that their insurance companies do not cover the recently approved generics.
“This medication has been the most commonly used inhaled medication for the past 25 or 30 years,” Dr Robyn Cohen, a pediatric pulmonologist at Boston Medical Center, told CNN.
“The fact that it’s being discontinued is going to be a huge shock to the system for patients, for families and for doctors,” Cohen told the outlet.
For some patients, switching to an entirely new product isn’t possible, doctors say.
Alternatives like Arnuity and Qvar, which are now the preferred treatments of some insurance carriers, are not appropriate for children due to the breath capacity needed to dispense the medication, Dr Christopher Oermann said in a Dec 8 news release from the American Academy of Pediatrics.
Both Flovent and the authorised generic can be used by patients 4 years and older, GSK says.
South-western province worst-hit by outbreak of crippling disease as 27 polio cases reported from Balochistan alone
Chronic pain lasts more than three months and affects about 30% of world's population
One of the mutations was also seen in another severe case from British Columbia, Canada
Cases reported in Tank district of KP and Sindh's Kashmore taking tally of both provinces to 19
Research finds drinking more than four cups of coffee in a day lowers risk of mouth, throat, head and neck cancers
Officials say one-and-a-half-year-old child diagnosed with crippling disease in Killa Abdullah district
